FDA's Withdrawn Reg On Data Fraud Hangs Over Zolgensma Incident

Democratic senators push data-challenged gene therapy into maw of drug pricing debate as they press acting commissioner Sharpless to bring the hammer down on Novartis, but also question US FDA's decision to withdraw the proposed rule last year.